Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Ключевой этап точечного лечения: Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Ключевой этап точечного лечения:
Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Владимир Борзенков, 68-летний пациент из Санкт-Петербурга, в последнее время прошел важный этап лечения CAR-T в Международной больнице Жияхуи в Шанхае – аферез. Этот процесс включает в себя сбор Т-клеток из организма пациента для дальнейшей генетической модификации и увеличения. Владимир выразил благодарность профессионализму лечебной команды и прозрачности лечебного процесса, что не только сняло его беспокойство, но и увеличило уверенность в успехе лечения. Больница Жияхуи использовала свои передовые устройства и технологии, чтобы обеспечить Владимиру плавный и эффективный опыт афереза, гарантируя высококачественный сбор Т-клеток и заложив прочный фундамент для следующих этапов лечения.
#CART #МножественнаяМиелома #ОдобрениеФУКАСО #Эквесел #БольницаЖияхуи #Шанхай #ВыжившийОтРака #КровяноеРак #Иммунотерапия #ПолностьюЧеловеческийCART
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital
Title: International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital
Content:
Singaporean patient, Ms. Teresa, recently experienced unique CAR-T therapy at Jiahui International Hospital in Shanghai. From scheduling to consultation, Jiahui Hospital demonstrated its top-notch service and medical expertise. During her initial visit, Teresa was impressed by the hospital’s modern facilities and the professionalism of the medical team.
The comprehensive assistance provided by the hospital, from language translation to medical consultation, ensured her comfort and peace of mind throughout the entire treatment process. Teresa shared, “From the moment I stepped into Jiahui, every meticulous care made me feel warm.” This visit not only strengthened her trust in Chinese medical services but also laid a solid foundation for her subsequent CAR-T therapy journey.
We will continue to monitor the progress of the patients’ treatment and provide follow-up reports.
#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
创新医疗服务的国际标准：新加坡患者在嘉会医院的初体验
创新医疗服务的国际标准：新加坡患者在嘉会医院的初体验
新加坡患者Teresa女士近期在上海嘉会国际医院体验了独特的CAR-T治疗。从预约到接诊，嘉会医院展示了其一流的服务和医疗水平。首次就诊中，Teresa对医院的现代化设施和医护团队的专业性印象深刻。医院提供的全面协助，从语言翻译到医疗咨询，确保了她在整个就诊过程中的舒适与安心。Teresa分享道：“从第一次步入嘉会，每一次细致的关怀都让我深感温馨。”此行不仅强化了她对中国医疗服务的信任，也为她后续的car-t治疗之路打下了坚实的基础。
我们将持续关注患者的治疗后续，并跟进报道。
#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope of patient
“When I first arrived, I couldn’t walk and had a lot of pain in my chest and back. Now, I don’t have these symptoms anymore, and I can walk for more than ten minutes every day.”
Meet Julian, a patient from Pakistan who faced the daunting challenge of a relapse in his battle against Multiple Myeloma. Despite undergoing various treatments, relief seemed elusive.
Julian’s wife stumbled upon groundbreaking research published by Xuzhou Medical University, highlighting innovative cell therapy for Multiple Myeloma developed by the Tumor Biotherapy Research Institute and affiliated hospitals.
Seeking further treatment, Julian and his wife embarked on a journey to Xuzhou Medical University Affiliated Hospital. Upon arrival, thorough examinations were conducted to assess his condition and formulate a tailored treatment plan.
Julian underwent T-cell collection at the Hematology Department’s Cell Collection Room, with the harvested cells processed into CAR-T cells by Xuzhou Medical University’s Cancer Research Institute. Two weeks later, he received an infusion of immune cells (CD19CAR-T cells, BCMACAR-T cells).
A month later, bone marrow cytology revealed complete remission of the primary disease. His attending physician continued medical observations, confirming positive treatment outcomes through comprehensive examinations.
“Previously, I couldn’t sit like this, and walking was very difficult. It was also very uncomfortable to lie down.”
”After receiving CAR-T treatment, you can see that I can now sit normally, walk normally, and my mobility is gradually increasing.
My improvement is very significant.”
From treatment initiation to Julian’s discharge and return home, the entire process took just one and a half months.
Julian’s journey stands as a beacon of hope, showcasing the transformative potential of innovative medical interventions in the fight against Multiple Myeloma.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company
Mutiple myeloma
#Legend Biotech
How to advance #CARTcell therapy to frontline treatment is the goal every CAR-T company strives for. On April 5, 2024, local time, Chinese pharmaceutical company Legend Biotech (LEGN.NS) shared exciting news as the U.S. Food and Drug Administration (#FDA) officially approved #ciltacabtageneautoleucel for treating relapsed or refractory multiple myeloma patients. This significant decision brings new hope to patients who have undergone first-line treatment and developed resistance to standard therapies.
#Ciltacabtagene autoleucel
Ciltacabtagene autoleucel becomes the world’s first CAR-T product approved for second-line treatment! This milestone event paves the way for Legend Biotech to enter the global CAR-T market. What’s even more inspiring is that just the day before, the FDA approved BMS’s CAR-T therapy Abecma for third-line treatment of multiple myeloma. The approval of ciltacabtagene autoleucel signifies the strong competitiveness and innovation capabilities of Chinese pharmaceutical companies in the CAR-T field.
Marketing
As early as February 28, 2022, ciltacabtagene autoleucel was first approved for marketing in the United States for the treatment of relapsed or refractory multiple myeloma in adults. As a pioneer of Chinese original CAR-T cell therapy, the successful market launch of this drug has won new glory for China’s biopharmaceutical industry. Currently, ciltacabtagene autoleucel is marketed in the United States, European Union, and Japan, and is also undergoing regulatory review in China, expected to be marketed domestically soon.
Personalized Immunotherapy
The CEO of Legend Biotech stated that the expanded indication of ciltacabtagene autoleucel is expected to change the treatment landscape of multiple myeloma, providing physicians and patients with a personalized immunotherapy option for early treatment. Multiple myeloma is an incurable and progressive hematologic malignancy, thus urgently requiring innovative treatment options, for which ciltacabtagene autoleucel is designed.
HOPE
The successful approval of ciltacabtagene autoleucel not only brings hope to patients but also outlines a new chapter for the future development of CAR-T therapy. In this hopeful moment, let’s look forward to CAR-T technology bringing health and happiness to more patients in the future!
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel
#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel
Multiple myeloma
Introduction:
In recent years, there has been a breakthrough in the research of #CART therapy for relapsed and refractory #multiplemyeloma (RRMM). This treatment method holds promise to address the challenges of inadequate response depth and short duration of response in #RRMM patients, offering hope for achieving minimal residual disease (#MRD) negativity and functional cure in this population.
Key Findings at EBMT:
The upcoming 50th European Society for Blood and Marrow Transplantation (EBMT) congress is set to unveil abstracts shedding light on the efficacy of targeted #BCMA CAR-T therapies. A recent abstract titled “Indirect Comparison of the Effectiveness of Targeted BCMA CAR-T Products in RRMM (#MAIC)” for the first time reveals efficacy comparisons among four BCMA CAR-T products. The study demonstrates that Equecabtagene Autoleucel outperforms other BCMA CAR-T therapies in terms of overall response rate (#ORR) and complete response (#CR) rate, offering significant hope for RRMM patients.
#Equecabtagene Autoleucel: Pioneering Fully-human BCMA #CARTTherapy:
#EquecabtageneAutoleucel, the world’s first approved Fully-human BCMA CAR-T therapy, received priority review and approval in China on June 30, 2023. The MAIC analysis underscores its favorable efficacy. This article provides a systematic analysis of the efficacy data of Equecabtagene Autoleucel in the Chinese population over the past two years, as revealed in the dynamic disclosures at various international academic conferences post-approval.
Efficacy Data Highlights:
– In the #FUMANBA-1 Ib/II clinical study conducted in China, the sCR/CR rate reached an impressive 82.4% among RRMM patients.
– The latest data presented at the 2023 International Myeloma Society (#IMS) conference demonstrated a MRD negativity rate of 97.8% among the enrolled patients, indicating substantial tumor burden reduction.
– With a median follow-up of 18.07 months, long-term efficacy data showcased remarkable outcomes, including a median PFS not yet reached, 12-month continuous MRD negativity rate of 81.7%, and 12-month PFS rate of 85.5%.
Differentiating Factors:
– Equecabtagene Autoleucel exhibited shorter median time to response (#TTR) compared to other CAR-T therapies, indicating faster onset of action.
– The dissociation kinetics of Equecabtagene Autoleucel closely resemble those of natural T cells, facilitating efficient activation, killing, and proliferation within the body.
– Its rapid dissociation pattern minimizes CAR-T cell exhaustion, ensuring sustained efficacy and long-term surveillance against tumor recurrence.
Conclusion:
The emergence of Equecabtagene Autoleucel heralds a new era in CAR-T therapy for RRMM, offering superior efficacy and durable responses. With its unique structural advantages and promising clinical data, Equecabtagene Autoleucel stands as a beacon of hope for RRMM patients worldwide, bringing them closer to achieving disease control and improved quality of life.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com
WhatsApp: +8613717959070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
cancer fight
🌟Mr. C from California, USA
It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.
🌞New treatment method
Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.
🌤Upon arriving in China,
Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.
🔥Hope and Courage
Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.
☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!
⭐️CAR-T therapy
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to:
💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070
✨The Medical Department will contact you as soon as receive the reports.
#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🌈 มุมมองของผู้เชี่ยวชาญ: ตัวเลือกการรักษาด้วย CAR-T ในผู้ป่วยไทย🌈
🌈 มุมมองของผู้เชี่ยวชาญ: ตัวเลือกการรักษาด้วย CAR-T ในผู้ป่วยไทย🌈
🌸 ในแผนกโรคเลือดของโรงพยาบาล Tongji ในเซี่ยงไฮ้ นายและนาง หลิวปิงได้ให้ข้อมูลรายละเอียดเกี่ยวกับสภาพการรักษาและการเดินทางในการรักษาของนาง P ผู้ป่วยชาวไทยที่มีโรคมะเร็งเม็ดเลือดหลายพัน. หลังจากที่ได้รับการรักษาหลายครั้งและมีการปลูกถ่ายเซลล์ระบบไตเองในประเทศไทย ผู้ป่วยมีอาการกลับมาซ้ำ โดยท้ายที่สุดเลือกเข้ารับการรักษาด้วย CAR-T ในประเทศจีน. นายและนาง หลิวปิงอธิบายว่าการรักษาด้วย CAR-T มีความหมายสำคัญในภาควิชามะเร็งเลือด เสนอประสิทธิผลที่น่าทึ่งสำหรับผู้ป่วยที่มีการกลับมาซ้ำหลายรอบ ยา CAR-T ที่เป็นมนุษย์สมบูรณ์ FUCASO (Eque-cel) ที่รู้จักกันดีเพื่อความมั่นใจในการเป็นตัวแทนของมนุษย์ลดการเป็นภูมิคุ้มกันและมีประสิทธิผลในระยะยาว ได้นำหวังให้ผู้ป่วยหายได้ โรงพยาบาล Tongji มีประสบการณ์ที่มากมายและการจัดการรอบด้านในการรักษาด้วย CAR-T ที่รับรองความปลอดภัยและความมีประสิทธิภาพ ให้บริการด้านการแพทย์ที่มีคุณภาพสูงให้แก่ผู้ป่วยระดับนานาชาติ
🌼 เราจะดำเนินการติดตามความคืบหน้าในการรักษาของผู้ป่วยต่อไปและให้ข้อมูลเพิ่มเติมต่อไป
#การรักษาโรคมะเร็ง #CART #ผู้เชี่ยวชาญด้านการแพทย์ #คุณภาพการรักษาสูง #การรักษาแบบพิเศษ #การรักษาสุดท้าย #มะเร็งเม็ดเลือด #การดูแลรักษาแบบครบวงจร #โรงพยาบาล #การรักษาทางการแพทย์ในระดับนานาชาติ #CARTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #cart
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Expert Perspective: Options for CAR-T Therapy in Thai Patients
🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈
🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.
🌼We will continue to follow up on the patient’s treatment progress and provide further updates.
#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🩸 Breakthrough in Multiple Myeloma Treatment! 🩺
🩸 Breakthrough in Multiple Myeloma Treatment! 🩺
LANCET
🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients.
Multiple myeloma, a malignant disease characterized by clonal plasma cell proliferation in the bone marrow, has remained incurable despite substantial progress in treatment methods such as systemic chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). However, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated activity in treating relapsed or refractory multiple myeloma. Nonetheless, the escape of BCMA-low or BCMA-negative myeloma cells has led to treatment resistance and relapse, highlighting the need to explore new targets.
💪In February 2023, a groundbreaking study titled “GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-center, single-arm, phase 1 trial” was published in The Lancet Haematology. The study aimed to evaluate the activity and safety of G-protein-coupled receptor class 5 member D (GPRC5D) CAR-T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.
🌈Promising Treatment Response with OriCAR-017 Infusion
All ten patients (100%) demonstrated an overall response, with 6 patients (60%) achieving a complete response and 4 patients (40%) showing very good partial responses. The patients with complete responses met stringent complete response criteria, and all patients achieved minimal residual disease (MRD) negativity by day 28. Serum M-protein concentrations gradually decreased, and patients’ clinical responses improved over time. The median time to the best response was 3.1 months, while the median time to a complete response or better was 4.1 months.
☀️Among the 5 patients who relapsed after BCMA CAR-T cell therapy, 2 patients achieved a stringent complete response, and 3 patients showed very good partial responses. Four patients had extramedullary disease at enrollment, with the largest tumor volume measuring 70 cm³. PET-CT scans revealed complete resolution of extramedullary lesions in three patients, while the extramedullary disease in one patient continued to shrink. Furthermore, no severe adverse events or treatment-related deaths were reported.
🌱Favorable Survival Outcomes after OriCAR-017 Infusion
⏰The median follow-up time for all patients was 238 days, with two patients progressing after achieving stringent complete remission. One patient experienced GPRC5D-positive relapse, with GPRC5D expression in malignant plasma cells increasing from 34.5% at baseline to 35.8% at relapse. The other patient experienced GPRC5D-negative relapse, with GPRC5D expression in malignant plasma cells decreasing from 86.8% at baseline to 6.9% at relapse. The remaining eight patients in ongoing remission were all negative for minimal residual disease, and no deaths occurred. The median progression-free survival time was not reached, but the estimated progression-free survival rate for all patients at nine months was 87.5%.
🧬Durable CAR-T Cell Persistence
✨CAR-T cell expansion was detected in all patients after infusion, with a median time to maximum CAR-T cell expansion (Cmax) of 10.0 days and a median Cmax of 7930 copies/μl. CAR-T cells exhibited favorable persistence in the body, with CAR-T cells still detectable in 90% of patients at one month, seven patients at three months, and four patients at six months.
🌟 The study results demonstrate that targeting GPRC5D with CAR-T cells in treating relapsed or refractory multiple myeloma patients is safe and shows promising activity. The observed targeted and off-target toxicities associated with GPRC5D were manageable, indicating the potential of GPRC5D as an effective immunotherapeutic target for multiple myeloma. These findings provide a foundation for subsequent phase 2 studies to further validate the efficacy and safety of targeting GPRC5D CAR-T cells in multiple myeloma.🦾
We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070
🔬 Stay tuned for more updates on this groundbreaking research! Together, we can conquer multiple myeloma!
#MultipleMyelomaResearch #CARTTherapy #GPRC5D #MedicalBreakthrough #cart #multiplemyeloma #chinesecart #cartcell #carttherapy #LANCET #Haematology #CARTCell
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀
🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀
ЧудесноеПутешествие
🌿Познакомьтесь с мистером Баранковым,
68-летним пациентом из Санкт-Петербурга, Россия, который внезапно был диагностирован с множественной миеломой в 2018 году. После четырех лет международных консультаций он обнаружил, что Китай значительно продвинулся в области терапии CAR-T по сравнению с европейскими медицинскими учреждениями в Испании, Мюнхене, Гейдельберге и других странах. Результаты лечения в Китае ведущие в мире.
🌱После четырех лет лечения и рецидивов
После неудачной традиционной химиотерапии и двух автологичных трансплантаций гемопоэтических стволовых клеток, у него появилась возможность провести онлайн-консультацию с экспертами Международной больницы Цзяхуи в Шанхае. Во время виртуальной консультации господин Баранков был впечатлен опытом китайской медицинской команды и потенциалом лечения с помощью полностью человеческого препарата CAR-T FUCASO (Eque-cel). Учитывая лидирующее положение Китая в области терапии CAR-T, более конкурентоспособные затраты и относительно короткое время ожидания, господин Баранков принял решение отправиться в Китай для получения лечения.
☘️
#ЧудесноеПутешествие #ТерапияCART #ПересечениеГраниц #MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀
🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀
Hope of patients
🌱Meet Mr. Barankov
a 68-year-old patient from Saint Petersburg, Russia, who was unexpectedly diagnosed with multiple myeloma in 2018. After four years of international consultations, he discovered that China has made significant advancements in CAR-T therapy compared to European medical institutions in Spain, Munich, Heidelberg, and others.
🌿The treatment outcomes in China are leading globally.
Following unsuccessful traditional chemotherapy and two autologous hematopoietic stem cell transplants, he had the opportunity for an online consultation with experts from Jiahui International Hospital in Shanghai. During the virtual consultation, Mr. Barankov was impressed by the expertise of the Chinese medical team and the therapeutic potential of the fully human CAR-T drug FUCASO (Eque-cel). Considering China’s leading position in CAR-T therapy, more competitive costs, and relatively shorter wait times, Mr. Barankov made a significant decision to travel to China for treatment.
☘️#MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART